Substance P

What is Substance P?

Substance P is an endogenous 11-amino-acid peptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) and the founding member of the tachykinin family of neuropeptides. It is encoded by the TAC1 gene (also called PPT-A, preprotachykinin-A), which produces precursor proteins that are processed to yield substance P along with the related tachykinin neurokinin A. Substance P acts predominantly at the G-protein-coupled neurokinin-1 receptor (NK1R), where it drives pain transmission from C-fiber primary afferents into the spinal cord dorsal horn, triggers neurogenic inflammation in peripheral tissues, mediates the emetic reflex in the brainstem, and modulates stress and emotional circuits. It is one of the most historically significant peptides in neuroscience — identified in 1931 by von Euler and Gaddum, it was the first peptide shown to act as a neurotransmitter. Substance P itself is a research peptide and endogenous signaling molecule, not a therapeutic, but the NK1 receptor it targets is a validated drug target: NK1R antagonists including aprepitant (Emend), fosaprepitant, netupitant, and rolapitant are FDA-approved for chemotherapy-induced nausea and vomiting.

What Substance P Is Investigated For

Substance P is almost always encountered as a research or pharmacology topic rather than a consumer peptide. Its importance comes from being the endogenous ligand for NK1R, the receptor that three FDA-approved drug classes have been built around. The strongest and most clinically impactful story is emesis: blocking NK1R with aprepitant (Emend) and its successors prevents chemotherapy-induced nausea and vomiting, and these drugs are part of standard oncology supportive care. The pain and neurogenic-inflammation story is mechanistically central — substance P is the prototypical C-fiber neurotransmitter and drives flare, wheal, and plasma extravasation — but translating that into oral analgesics has been disappointing. The best-known cautionary tale is depression: Merck's MK-869 (aprepitant) produced a striking Phase II antidepressant signal in 1998, but multiple Phase III trials failed to beat placebo. That arc is one of the most instructive examples in modern CNS drug development of a validated receptor target that did not deliver the hoped-for psychiatric indication. Substance P itself is not used as a therapeutic and has no consumer use case — the conversation that matters is about the receptor it hits, not the peptide itself.

History & Discovery

Substance P's discovery in 1931 places it among the oldest peptides in biological research, and its naming and characterization span one of the longest arcs in neuropeptide history. Ulf von Euler, then a young Swedish physiologist working with Henry Dale and John Gaddum at the National Institute for Medical Research in London, identified a bioactive preparation in horse brain and intestine that produced atropine-resistant smooth muscle contraction and hypotension. Gaddum and von Euler labeled the extract 'preparation P' — the 'P' typically attributed to the powdered form of the tissue extracts — and published the observation in the 1931 Journal of Physiology. The term 'Substance P' persisted informally as work on the unidentified factor continued over the following decades, and it is one of very few molecules whose placeholder laboratory name became its permanent scientific name. Substance P's identity as an 11-residue peptide was not established until 1971, forty years after the original observation. Susan Leeman, Michael Chang, and Hugh Niall, working at Brandeis University, purified the peptide from bovine hypothalamus and sequenced it — Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 — publishing the result in Nature New Biology. The isolation and sequencing confirmed substance P as a bona fide peptide and established it as the founding member of what would become the tachykinin family, a group of structurally related peptides sharing the C-terminal motif Phe-X-Gly-Leu-Met-NH2. The peptide's role as a neurotransmitter — released from primary afferent sensory neurons, acting on a specific receptor to transmit nociceptive information — was elaborated through the 1970s and 1980s. The neurokinin-1 receptor was cloned and functionally characterized in 1989 (rat) and 1991 (human), formally identifying the G-protein-coupled receptor responsible for most of substance P's known effects. Cloning opened the door to systematic medicinal chemistry: small-molecule NK1R antagonists entered preclinical development in the early 1990s at multiple pharmaceutical companies, with Merck's MK-869 (later named aprepitant) emerging as a leading candidate. Two parallel clinical stories unfolded. In oncology, aprepitant demonstrated clear efficacy for preventing chemotherapy-induced nausea and vomiting, with Hesketh and colleagues reporting the pivotal Phase III trial in 2003, leading to FDA approval of Emend and subsequent approvals for fosaprepitant (intravenous prodrug), netupitant (as NEPA combination), and rolapitant. In psychiatry, the story went the other way. In 1998, Mark Kramer, Nadia Rupniak, and Merck colleagues published a Science paper reporting that MK-869 produced antidepressant effects comparable to paroxetine in a Phase II trial, proposing that NK1R antagonism represented a mechanistically distinct antidepressant strategy. The report generated enormous excitement, and Merck advanced the compound into Phase III for depression. Five subsequent Phase III trials, pooled by Keller and colleagues in 2006, showed that aprepitant consistently failed to separate from placebo on the Hamilton Depression Rating Scale, while paroxetine comparator arms in those same trials behaved as expected. The NK1R-for-depression program was abandoned — an instructive modern example of a mechanistically elegant target that did not deliver in a psychiatric indication. Aprepitant went on to become a mainstay of oncology supportive care rather than a novel antidepressant.

How It Works

Substance P is a short peptide your body makes naturally. It is released by sensory nerves — especially the thin C-fibers that carry pain signals — and it locks onto a receptor called NK1 on nearby cells. When this happens in the spinal cord, you feel pain. When it happens in skin or airway, you get swelling, redness, and inflammation. When it happens in the brainstem, you get nausea and vomiting. Because of this last role, drugs that block the NK1 receptor (such as aprepitant / Emend) are used to prevent the severe nausea caused by chemotherapy. The peptide itself is not a medicine — the useful drugs are the blockers that stop it from acting.

Substance P is produced by processing of the TAC1 (preprotachykinin-A, PPT-A) gene product, which also gives rise to neurokinin A via alternative splicing and differential processing. The mature 11-residue peptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) is C-terminally amidated — a common post-translational modification across bioactive peptides that increases receptor affinity and resistance to carboxypeptidase degradation. It is expressed densely in small-diameter sensory neurons (peptidergic C-fibers) of the dorsal root and trigeminal ganglia, in specific intrinsic neurons of the central nervous system including the basal ganglia and amygdala, and in enteric neurons of the gut. Substance P's principal pharmacological target is the neurokinin-1 receptor (NK1R, encoded by TACR1), a G-protein-coupled receptor of the rhodopsin family. NK1R signals primarily through Gq, activating phospholipase C, generating inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium, and activating protein kinase C. Additional signaling through Gs (cAMP elevation) and downstream MAP kinase pathways contributes to receptor internalization, transcriptional effects, and the characteristic long-lasting 'windup' associated with substance P-driven spinal sensitization. Substance P also binds NK2 and NK3 receptors with lower affinity, with neurokinin A and neurokinin B as the preferred endogenous ligands for those two subtypes respectively. In the spinal cord dorsal horn, substance P is co-released with glutamate from central terminals of C-fibers in response to noxious stimulation. Its NK1R-mediated actions on second-order dorsal horn neurons drive slow, long-lasting excitatory postsynaptic potentials that amplify nociceptive input and contribute to central sensitization. In peripheral tissues, antidromic substance P release from sensory nerve terminals produces neurogenic inflammation — vasodilation, plasma extravasation, mast cell degranulation, and immune cell recruitment — the cellular substrate of the wheal-and-flare response. In the brainstem, dense NK1R expression in the area postrema, nucleus tractus solitarius, and dorsal motor nucleus of the vagus places substance P at the center of the emetic reflex; this is the anatomical basis for the antiemetic efficacy of NK1R antagonists. In higher brain regions, substance P and NK1R expression in the amygdala, hypothalamus, and periaqueductal gray implicate the system in stress, anxiety, and affective regulation — the rationale for the since-abandoned NK1R-antagonist-for-depression program.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Substance P:

• 01Why the NK1R antagonists failed in depression despite a robust Phase II signal remains incompletely understood — whether the Phase II result was a chance finding, whether receptor occupancy achieved in Phase III was inadequate, or whether the target simply does not mediate clinical antidepressant effect in unselected major depressive disorder populations.
• 02Translational gap between neurogenic-inflammation biology and clinically useful anti-inflammatory therapy — substance P-driven inflammation is mechanistically well-characterized, but NK1R antagonists have not emerged as practical anti-inflammatory drugs outside the emesis indication.
• 03Role of substance P in fibromyalgia, chronic pain, and functional pain syndromes — elevated cerebrospinal fluid substance P has been reported in fibromyalgia for decades, but has not translated into a clinical indication for NK1R-targeted therapy in chronic pain.
• 04Whether substance P-selective manipulation (versus broader tachykinin system modulation) could be therapeutically useful in pruritus, cough, bladder hyperactivity, or inflammatory bowel disease — areas of ongoing but unresolved investigation.
• 05Whether substance P biology differs meaningfully between humans and rodents in ways that contribute to translational failures — rodents are poor vomiting models, and species differences in NK1R pharmacology and central nervous system distribution have been documented.

Forms & Administration

Substance P is a research peptide and endogenous signaling molecule — it is not formulated or approved for therapeutic administration. In laboratory settings it is used in receptor-binding assays, isolated-tissue pharmacology, intradermal wheal-and-flare testing, and intrathecal or intracerebroventricular administration in animal models of pain. The clinically relevant products at the NK1 receptor are antagonists, not agonists: oral aprepitant (Emend), intravenous fosaprepitant (Emend IV), oral netupitant (as the fixed-dose combination NEPA, netupitant/palonosetron), and oral rolapitant (Varubi). These drugs are approved for the prevention of chemotherapy-induced nausea and vomiting and are administered by clinicians in oncology and supportive-care settings.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions